Pioglitazone hydrochloride

Sterilised isotonic aqueous solution containing 8.5% DQS (pH 7.5) was supplied by our company’s formulation facility and diluted with basal Ham’s F-12 medium (Nacalai Tesque, Kyoto, Japan) before use. In addition, the following reagents were used in this study: recombinant human epidermal growth factor (hEGF; Corning, One Riverfront Plaza, NY); collagenase A, dispase II and O-phosphorylethanolamine (Millipore Sigma, St. Louise, MO); pioglitazone hydrochloride (Tokyo Chemical Industry, Tokyo, Japan); ITS-X (100 ×) and Nile red dye (Thermo Fisher Scientific, Waltham, MA); Ca²⁺ ionophore ionomycin calcium (FUJIFILM Wako Pure Chemical, Osaka, Japan); selective P2Y₂ receptor antagonist AR-C118925XX (Bio-Techne, Minneapolis, MN) and intracellular Ca²⁺ chelator BAPTA-AM (Abcam, Cambridge, UK); and PrimeGel Agarose PCR-Sieve (Takara Bio, Shiga, Japan). The other products and reagent kits used in this study are described in the experimental procedures.

Azilsartan, carvedilol, ciprofloxacin hydrochloride hydrate, dipyridamole, dantrolene sodium hydrate, furosemide, febuxostat, haloperidol, losartan potassium, lurasidone, montelukast sodium hydrate, and pioglitazone hydrochloride were purchased from Tokyo Chemical Industry Co., Ltd. Tamoxifen citrate and tosufloxacin tosylate hydrate were purchased from FUJIFILM Wako Pure Chemical Corporation. Raltegravir was extracted from the tablet. The manufacturers of the IR products are summarized in Table II.